[Skip to Content]
[Skip to Content Landing]
October 5, 1994

The Efficacy of Zidovudine Is Time Limited-Reply

Author Affiliations

University of Copenhagen Copenhagen, Denmark
Royal Free Hospital London, England

JAMA. 1994;272(13):1001-1002. doi:10.1001/jama.1994.03520130035019

In Reply.  —We appreciate the interest in the results presented in our recent publication. Drs Berman and Wenglin are correct in their interpretation of our results insofar as zidovudine seems to have a beneficial influence on survival when it is initiated in patients with advanced human immunodeficiency virus (HIV) infection. As also pointed out in the "Comment" section of our article, the results agree with the only placebo-controlled study1 and several observational studies2 in patient groups with similar advanced HIV infection as in our population (ie, a survival benefit within the first months after starting zidovudine). However, because of the large number of patients studied, we were also able to suggest whether the effect persisted for extended periods of time; we found this not to be true. Whether optimal dosage and combination antiretroviral therapy will eventually affect survival of AIDS patients, as suggested by Berman and Wenglin, awaits

First Page Preview View Large
First page PDF preview
First page PDF preview